Health Condition 1: null- scheduled to undergo awake nasal fibreoptic intubation
Conditions
Interventions
Intervention1: Transtracheal injection: Lignocaine 2 mL 2% infiltrated transtracheally
Control Intervention1: spray as you go: Lignocaine 2% 2 mL is sprayed below the vocal cords through the fibreopti
Sponsors
Kasturba Hospital KMC Manipal
Eligibility
Inclusion criteria
Inclusion criteria: All patients above 18 years scheduled to undergo awake nasal fibreoptic intubation
Exclusion criteria
Exclusion criteria: • ASA physical status IV • Raised intracranial pressure • Uncontrolled seizure disorder and/or known psychiatric illness • Currently on (in the past 14 days) treatment with an α2 agonist or antagonist • Patients in whom dexmedetomidine or benzodiazepine administration is contraindicated • Patients with acute unstable angina, laboratory confirmed acute myocardial infarction within the past 6 weeks, heart rate • Elevated ALT and/or AST values of > 2 times the upper limit of normal.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Scores observed during fibreoptic scopy, intubation and postintubation [Composite score, postintubation score, anaesthesiologistsâ?? perception of ease of intubation] and postoperative surveyTimepoint: During fibrescopy and the survey that is done 24 h following surgery | — |
Secondary
| Measure | Time frame |
|---|---|
| Fibrescopy time, intubation time, number of attempts at intubation, haemodynamic changes and complicationsTimepoint: During fibrescopy and intubation | — |
Countries
India
Contacts
Public ContactUmesh G
KMC, Manipal
Outcome results
None listed